Index
RUT
Market Cap
527.55M
Enterprise Value
438.47M
Income
26.72M
Sales
231.24M
Book/sh
2.71
Cash/sh
1.82
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
179
IPO
Apr 20, 2012
P/E
19.79
Forward P/E
-
PEG
-
P/S
2.28
P/B
3.77
P/C
5.62
P/FCF
12.82
EV/EBITDA
10.74
EV/Sales
1.90
Quick Ratio
2.64
Current Ratio
2.91
Debt/Eq
0.03
LT Debt/Eq
0.03
Option/Short
Yes / Yes
EPS (ttm)
0.52
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
0.05% 0.29%
EPS Y/Y TTM
-46.26%
Sales Y/Y TTM
-2.86%
EPS Q/Q
33.30%
Sales Q/Q
7.75%
Insider Own
22.35%
Insider Trans
-1.78%
Inst Own
67.66%
Inst Trans
2.45%
ROA
13.78%
ROE
21.97%
ROIC
18.70%
Gross Margin
74.83%
Oper. Margin
13.16%
Profit Margin
11.55%
SMA20
-2.18%
SMA50
3.69%
SMA200
28.52%
Trades
Shs Outstand
51.10M
Shs Float
40.08M
52W High
11.50 -11.13%
52W Low
4.57 123.39%
Volatility
3.43% 4.36%
ATR (14)
0.42
RSI (14)
49.18
Beta
1.34
Rel Volume
1.22
Avg Volume
334.20K
Volume
406,521
Perf Week
-6.41%
Perf Month
5.69%
Perf Quarter
27.91%
Perf Half Y
39.05%
Perf YTD
71.76%
Perf Year
102.78%
Perf 3Y
267.63%
Perf 5Y
55.32%
Perf 10Y
-70.46%
Prev Close
10.18
Price
10.22
Change %
0.39%
Analysts 10 incl. previous ratings
Rating Distribution 3 Buy · 4 Hold · 3 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Sep 28, 2021 Upgrade C Citigroup
Neutral → Buy $11 +7.6% Jun 25, 2020 Resumed B BofA/Merrill
Underperform $9 -11.9% Oct 08, 2019 Downgrade G Goldman
Neutral → Sell $24 → $8 -21.7% May 10, 2019 Downgrade C Citigroup
Buy → Neutral $24 +134.8% May 10, 2019 Downgrade C Cantor Fitzgerald
Overweight → Neutral $57 → $20 +95.7% Jan 17, 2019 Initiated L Leerink Partners
Mkt Perform $21 +105.5% Jan 03, 2019 Downgrade G Guggenheim
Buy → Neutral Nov 19, 2018 Upgrade G Goldman
Sell → Neutral Nov 02, 2018 Downgrade J JP Morgan
Neutral → Underweight Nov 02, 2018 Downgrade B BofA/Merrill
Buy → Underperform Oct 01, 2018 Initiated C Cantor Fitzgerald
Overweight $75 +633.9% Sep 17, 2018 Initiated G Goldman
Sell $42 +311.0% May 11, 2018 Reiterated S Stifel
Buy $95 → $87 +751.3% Nov 10, 2017 Reiterated R RBC Capital Mkts
Sector Perform $92 → $108 +956.8% Nov 10, 2017 Reiterated C Citigroup
Buy $156 → $164 +1,504.7% Oct 02, 2017 Reiterated S Stifel
Buy $110 → $130 +1,172.0% Sep 11, 2017 Reiterated C Credit Suisse
Outperform $118 → $136 +1,230.7% Jul 10, 2017 Resumed L Leerink Partners
Outperform $115 +1,025.2% Jun 06, 2017 Reiterated R RBC Capital Mkts
Sector Perform $60 → $88 +761.1% May 25, 2017 Reiterated R RBC Capital Mkts
Sector Perform $40 → $60 +487.1%
Show Previous Ratings
Oct-28-26 08:39PM
Oct-22-26 04:11PM
Oct-05-26 05:00PM
Sep-17-26 04:07PM
Sep-09-26 04:11PM
05:00PM
Loading…
Sep-03-26 05:00PM
Aug-07-26 01:10AM
Aug-06-26 05:22PM
Aug-05-26 05:00PM
Jul-23-26 04:10PM
Jul-02-26 05:03PM
Jun-03-26 05:00PM
May-07-26 05:37PM
04:05PM
May-06-26 05:15PM
04:15PM
Loading…
Apr-23-26 04:15PM
Apr-02-26 05:15PM
Feb-27-26 12:35PM
01:12AM
12:05AM
Feb-26-26 06:45PM
05:15PM
(Associated Press Finance)
04:05PM
Feb-24-26 07:30PM
Feb-23-26 04:15PM
Feb-12-26 04:07PM
Feb-10-26 05:25PM
Feb-04-26 05:05PM
Jan-07-26 05:15PM
Dec-31-25 11:20AM
04:10PM
Loading…
Dec-22-25 04:10PM
Dec-17-25 11:26AM
Dec-02-25 05:15PM
Nov-27-25 11:58AM
Nov-07-25 05:05PM
(Business Wire)
+22.24%
-21.04%
10:53AM
12:03AM
Nov-06-25 06:00PM
04:55PM
(Associated Press Finance)
04:05PM
Nov-05-25 05:20PM
Oct-23-25 04:10PM
Oct-09-25 05:06AM
Oct-02-25 05:21PM
Sep-17-25 02:27PM
Sep-15-25 12:42PM
Sep-04-25 05:25PM
Sep-02-25 04:07PM
Sep-01-25 09:55AM
Aug-28-25 09:40AM
Aug-13-25 09:15AM
Aug-12-25 09:40AM
09:15AM
09:11AM
Aug-08-25 05:00PM
(Business Wire)
+12.16%
+31.44%
10:26AM
Aug-07-25 05:55PM
04:56PM
(Associated Press Finance)
04:05PM
Aug-06-25 06:05PM
Jul-24-25 04:15PM
Jul-15-25 08:31AM
Jul-14-25 09:40AM
Jul-10-25 08:50AM
Jul-08-25 10:31AM
Jul-04-25 08:35AM
Jul-02-25 05:03PM
08:34AM
Jul-01-25 11:55AM
10:05AM
Jun-30-25 10:40AM
Jun-27-25 10:58AM
09:40AM
Jun-25-25 11:30AM
Jun-24-25 08:50AM
Jun-19-25 11:11AM
Jun-18-25 10:51AM
Jun-12-25 11:30AM
Jun-11-25 09:40AM
Jun-04-25 05:33PM
May-28-25 08:50AM
May-26-25 09:40AM
May-12-25 08:50AM
May-09-25 09:40AM
08:48AM
03:39AM
May-08-25 05:55PM
04:52PM
(Associated Press Finance)
04:05PM
May-07-25 05:20PM
01:25PM
11:55AM
08:10AM
May-06-25 05:15PM
May-05-25 09:15AM
May-01-25 08:05AM
Apr-30-25 12:00PM
06:00AM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
WILSON TROY EDWARD Director Sep 14 '26 Sale 9.10 5,000 45,500 54,750 Sep 16 09:13 PM Cesano Alessandra Director Sep 14 '26 Option Exercise 2.93 50,000 146,500 118,850 Sep 16 09:06 PM Cesano Alessandra Director Sep 14 '26 Sale 9.12 62,150 566,994 56,700 Sep 16 09:06 PM Cesano Alessandra Director Sep 14 '26 Proposed Sale 9.10 62,150 565,565 Sep 14 12:05 PM WILSON TROY EDWARD Director Sep 14 '26 Proposed Sale 9.10 5,000 45,500 Sep 14 12:01 PM AUERBACH ALAN H President and CEO Jul 06 '26 Sale 8.26 44,058 364,051 7,261,671 Jul 08 08:21 PM HUNT DOUGLAS M See Remarks Jul 06 '26 Sale 8.26 8,460 69,905 196,841 Jul 08 08:19 PM NOUGUES MAXIMO F Chief Financial Officer Jul 06 '26 Sale 8.26 9,386 77,557 230,637 Jul 08 08:18 PM AUERBACH ALAN H Officer Jul 06 '26 Proposed Sale 8.26 44,058 364,042 Jul 06 04:56 PM HUNT DOUGLAS M Officer Jul 06 '26 Proposed Sale 8.26 8,460 69,903 Jul 06 04:49 PM NOUGUES MAXIMO F Officer Jul 06 '26 Proposed Sale 8.26 9,386 77,555 Jul 06 04:44 PM WILSON TROY EDWARD Director Jun 12 '26 Sale 7.20 10,800 77,748 59,750 Jun 15 08:16 PM Stuglik Brian M Director Jun 12 '26 Sale 7.20 8,100 58,311 113,858 Jun 15 08:14 PM Senderowicz Adrian Director Jun 12 '26 Sale 7.20 27,000 194,311 27,000 Jun 15 08:13 PM MOYES JAY M Director Jun 12 '26 Sale 7.22 22,000 158,796 58,322 Jun 15 08:10 PM Dorval Allison Director Jun 12 '26 Sale 7.20 11,610 83,579 90,780 Jun 15 08:09 PM Senderowicz Adrian Director Jun 12 '26 Proposed Sale 7.26 27,000 196,020 Jun 12 10:39 AM MOYES JAY M Director Jun 12 '26 Proposed Sale 7.26 22,000 159,720 Jun 12 10:37 AM Dorval Allison Director Jun 12 '26 Proposed Sale 7.26 11,610 84,289 Jun 12 10:33 AM Stuglik Brian M Director Jun 12 '26 Proposed Sale 7.26 8,100 58,806 Jun 12 10:23 AM WILSON TROY EDWARD Director Jun 12 '26 Proposed Sale 7.26 10,800 78,408 Jun 12 09:58 AM AUERBACH ALAN H President and CEO Jan 07 '26 Sale 5.88 18,012 105,893 7,145,951 Jan 08 08:27 PM AUERBACH ALAN H President and CEO Jan 06 '26 Sale 5.84 16,938 98,986 7,163,963 Jan 08 08:27 PM HUNT DOUGLAS M See Remarks Jan 07 '26 Sale 5.88 5,014 29,477 155,907 Jan 08 08:15 PM HUNT DOUGLAS M See Remarks Jan 06 '26 Sale 5.84 3,973 23,218 160,921 Jan 08 08:15 PM NOUGUES MAXIMO F Chief Financial Officer Jan 07 '26 Sale 5.88 6,405 37,655 193,284 Jan 08 08:14 PM NOUGUES MAXIMO F Chief Financial Officer Jan 06 '26 Sale 5.84 4,540 26,532 199,689 Jan 08 08:14 PM AUERBACH ALAN H Officer Jan 07 '26 Proposed Sale 5.88 18,012 105,893 Jan 07 04:28 PM HUNT DOUGLAS M Officer Jan 07 '26 Proposed Sale 5.88 5,014 29,477 Jan 07 04:25 PM NOUGUES MAXIMO F Officer Jan 07 '26 Proposed Sale 5.88 6,405 37,655 Jan 07 04:24 PM NOUGUES MAXIMO F Officer Jan 06 '26 Proposed Sale 5.84 4,540 26,530 Jan 06 04:53 PM HUNT DOUGLAS M Officer Jan 06 '26 Proposed Sale 5.84 3,973 23,217 Jan 06 04:45 PM AUERBACH ALAN H Officer Jan 06 '26 Proposed Sale 5.84 16,938 98,979 Jan 06 04:44 PM MILLER MICHAEL PATRICK Director Nov 11 '25 Sale 4.86 20,000 97,228 54,000 Nov 13 04:41 PM MILLER MICHAEL PATRICK Director Nov 11 '25 Proposed Sale 4.86 20,000 97,228 Nov 12 08:29 AM
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
Founder Mr. Alan H. Auerbach
CFO & Principal Accounting Officer Mr. Maximo F. Nougues
FRAPS Mr. Douglas Hunt B.Sc.
Chief Accounting Officer Mr. Gordon G. Esplin
Senior Director of Investor Relations Mr. Mariann Ohanesian